FBT
First Trust NYSE Arca Biotechnology Index Fund
NYSEArcaUSDETF / FUND
DELAYED
Buy
+32/100
Last price
264.97
▼ 5.96 (2.20%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
270.93
Day high
272.86
Day low
262.35
Volume
71.46K
Market cap
—
P/E (TTM)
28.84
52W range
182.08 – 275.23
Trailing performance
Returnvs SPY
1W
-2.79%
-4.7%
1M
-2.20%
-3.4%
3M
+4.48%
-0.0%
6M
+31.88%
+13.7%
YTD
+28.30%
+14.1%
1Y
+40.09%
+23.7%
3Y
+81.05%
-1.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Top holdings
Sector exposure
Healthcare
100.00%
Fund profile
Fund familyFirst Trust
CategoryHealth
Legal typeExchange Traded Fund
Expense ratio0.55%
Turnover37.0%
Total net assets$19.49M
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on FBT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E28.84
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Options analytics
Put / call volume
1.67
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
240.00
-9.4% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+6.2%
Puts bid over calls
Call volume
3
Contracts, this expiry
Put volume
5
Contracts, this expiry
Heaviest call OI
275.00
0 contracts
Heaviest put OI
240.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
270.17
-1.93% from price
SMA 20
268.33
-1.25% from price
SMA 50
264.08
+0.34% from price
SMA 100
248.61
+6.58% from price
SMA 200
227.89
+16.27% from price
EMA 12
269.00
-1.50% from price
EMA 26
267.84
-1.07% from price
EMA 50
262.77
+0.84% from price
RSI (14)
46.4
Neutral
MACD (12,26,9)
1.16
Hist -0.88
ATR (14)
5.16
1.95% of price
Realised vol 30D
20.3%
Annualised
Bollinger upper
276.27
20, 2σ
Bollinger lower
260.39
20, 2σ
50 / 200 cross
Golden
264.08 vs 227.89
Trend bias
Above 200
+16.27%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.77
Less volatile than market
Correlation to SPY
0.46
Loosely linked
Realised vol 30D
20.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-14.3%
Peak to trough
Max drawdown 5Y
-27.4%
Peak to trough
ATR 14
5.16
1.95% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Zacks · 16d ago
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Zacks · 26d ago
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Zacks · 36d ago
The Zacks Analyst Blog Highlights Amgen, Crinetics, FBT, BBH and BBP
Zacks · 47d ago
Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth
Zacks · 48d ago
FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It
24/7 Wall St. · 72d ago
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Zacks · 89d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.